A Phase 1 interventional study of Betaxolol and topical betaxolol in Development of Side Effects From Betaxolol, sponsored by Smith-Kettlewell Eye Research Institute. Completed. Open to participants aged 32 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2013-01-03.
Sponsored by Smith-Kettlewell Eye Research Institute · Phase 1, Interventional, and Prevention
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.
815 studies on the registry are indexed under Retinal Diseases; 105 are open to participants now.
This study's enrollment of 23 is below the median of 60 across 500 interventional studies indexed under Retinal Diseases.
Browse Retinal Diseases studies →Smith-Kettlewell Eye Research Institute is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
betaxolol 0.25% 2 per day for 3 weeks
Drug: Betaxolol
masked labeling also 2 per day administration
Drug: topical betaxolol
given topically
development of apnea and or bradycardia
babies were monitored and HR/RR monitored and recorded by masked observers, periodically
Time frame: 3 weeks
development of ROP requiring treatment
Type I ROP was used as a secondary outcome measure
Time frame: 7 weeks
No study locations are listed for this record.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Smith-Kettlewell Eye Research Institute